Johnson & Johnson (J&J), which is struggling with slowdown of demand for its consumer products in India, sold its largest manufacturing plant in the country - at Penjerla in Telangana - to Hetero on a slump sale basis.
Pharmaceuticals firm Hetero on Monday said it has acquired the manufacturing plant of Johnson & Johnson at Penjerla in Telangana and will invest additional Rs 600 crore on its upgradation. According to sources, the company has acquired the plant for Rs 130 crore.
The subject expert committee under the drug regulator of India has sought some documents from Hetero Biopharma which had approached the drug authority to launch a generic version of the Sputnik Light Covid-19 vaccine.
Hetero Labs Limited on Health Canada Inspection List
New Delhi, Dec 28 (PTI) With the DCGI approving the anti-COVID-19 pill Molnupiravir for emergency use in the country, Strides Pharma on Tuesday said it will launch the capsule immediately while six other homegrown pharma companies announced rolling out their generic versions of the drug shortly.
The Hyderabad-based Natco and Hetero Pharma, which have carried out phase 3 clinical trials on the molnupiravir anti-viral drug developed by US based pharma company Merck, have submitted the results of their clinical trials to the DCGI and have sought market authorization for the same in India.
The availability later this month of Hetero's biosimilar tocilizumab, ostensibly a less pricey product, could place India in a relatively better situation to cope with any demand spurt should another wave of COVID-19 strike. Innovator product Actemra is expected to be in short supply, going by current trends, given the unprecedented worldwide demand.
India`s Hetero gets emergency use nod to make Roche`s COVID-19 drug
India's Hetero Labs said on Friday it sought emergency use nod from the local regulator for Merck's COVID-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases.nnReporting by Vishwadha Chander in Bengalur
Hetero, a globally renowned vertically integrated pharmaceutical organization, announced the interim clinical results from phase III clinical trials of molnupiravir in mild Covid-19 patients conducted across multiple Covid-19 dedicated hospital sites across India.